This conference would not be possible without the many contributions from affected families and the gracious commitment of many corporations and organizations. ISMRD acknowledges the following for their financial and logistical support, without whom this international gathering would not be possible:

• National Institute of Neurological Diseases & Stroke
• Office of Rare Diseases
• Amicus Therapeutics
• Novartis
• National MPS Society (USA)
• Global Organization for Lysosomal Diseases
• Sigma Tau Pharmaceuticals

 

Funding for this conference was made possible (in part) by NS060583 from National Institute of Neurological Disorders and Stroke (NINDS) and the Office of Rare Diseases (ORD). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.